| scholarly article | Q13442814 |
| P50 | author | Frederik Holst | Q38601189 |
| Ronald Simon | Q40046025 | ||
| P2093 | author name string | Luigi Terracciano | |
| Guido Sauter | |||
| Christian Ruiz | |||
| Olaf Hellwinkel | |||
| Annette Lebeau | |||
| Zeenath Jehan | |||
| Fritz Jänicke | |||
| Phillip R Stahl | |||
| Khawla Al-Kuraya | |||
| Marc Wendland | |||
| P2860 | cites work | Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer | Q33845160 |
| Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer | Q34367966 | ||
| Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials | Q34451337 | ||
| Tamoxifen in premenopausal patients with metastatic breast cancer: a review | Q37748649 | ||
| Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab | Q38440789 | ||
| Mammary cancer: selective action of the estrogen receptor complex | Q43532737 | ||
| The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). | Q43857221 | ||
| Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment | Q46641346 | ||
| Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection ofcyclin D1 in breast andcyclin E in ovarian tumors | Q57287626 | ||
| Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer | Q69746563 | ||
| Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors | Q72825296 | ||
| Estrogen receptor expression in benign breast epithelium and breast cancer risk | Q74038716 | ||
| Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer | Q74299719 | ||
| Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer | Q77996259 | ||
| Prognostic relevance of gene amplifications and coamplifications in breast cancer | Q81085059 | ||
| Tissue microarrays for comparing molecular features with proliferation activity in breast cancer | Q81581418 | ||
| Oestrogen receptor expression in the normal and pre-cancerous breast | Q93924363 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 655-660 | |
| P577 | publication date | 2007-04-08 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. | |
| P478 | volume | 39 |
| Q35574894 | A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation. |
| Q36756436 | A human estrogen receptor (ER)alpha mutation with differential responsiveness to nonsteroidal ligands: novel approaches for studying mechanism of ER action |
| Q34317299 | ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1 |
| Q44823361 | Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan |
| Q39890928 | Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. |
| Q36393272 | Amping up estrogen receptors in breast cancer |
| Q38416045 | Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer |
| Q37606324 | Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer |
| Q36135807 | Androgen receptor as a targeted therapy for breast cancer. |
| Q28074060 | Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer? |
| Q90069820 | Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil |
| Q36449789 | Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk |
| Q37328115 | Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model |
| Q39667297 | Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. |
| Q46798510 | Biomarkers identified for prostate cancer patients through genome-scale screening |
| Q39820073 | Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer |
| Q53116366 | CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. |
| Q38028797 | Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? |
| Q28069804 | Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery |
| Q88454452 | CellExpress: a comprehensive microarray-based cancer cell line and clinical sample gene expression analysis online system |
| Q35590038 | Classifying ten types of major cancers based on reverse phase protein array profiles |
| Q64249317 | Clinical and Biological Significance of Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients |
| Q36287107 | Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer |
| Q91854850 | Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer |
| Q34965545 | Comparison and identification of estrogen-receptor related gene expression profiles in breast cancer of different ethnic origins |
| Q98288891 | Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations |
| Q34155176 | Computational identification of surrogate genes for prostate cancer phases using machine learning and molecular network analysis |
| Q81535537 | Conflicting evidence on the frequency of ESR1 amplification in breast cancer |
| Q91790671 | Context-Specific Coordinately Regulatory Network Prioritize Breast Cancer Genetic Risk Factors |
| Q36778107 | Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. |
| Q41438471 | Crucial microRNAs and genes of human primary breast cancer explored by microRNA-mRNA integrated analysis. |
| Q37306557 | Current research topics in endocrine therapy for breast cancer |
| Q40514940 | Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma |
| Q37763102 | DNA amplifications in breast cancer: genotypic-phenotypic correlations |
| Q52691439 | DNA-mediated dimerization on a compact sequence signature controls enhancer engagement and regulation by FOXA1. |
| Q36943634 | Detection of DNA copy number alterations in cancer by array comparative genomic hybridization |
| Q36840167 | Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer |
| Q37454936 | Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer |
| Q35479617 | ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer |
| Q35075706 | ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous |
| Q60529810 | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
| Q36643091 | ESR1 and EGF genetic variation in relation to breast cancer risk and survival |
| Q42561463 | ESR1 gene amplification in breast cancer: a common phenomenon? |
| Q60035714 | ESR1 gene amplification in breast cancer: a common phenomenon? |
| Q81535508 | ESR1 gene amplification in breast cancer: a common phenomenon? |
| Q94702580 | ESR1 gene amplification in breast cancer: a common phenomenon? |
| Q82153025 | ESR1 gene amplification: another mechanism regulating the cellular levels of ERα |
| Q38403294 | ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry |
| Q21563388 | ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1 |
| Q91792171 | ESR1 mutations: Pièce de résistance |
| Q37013898 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer |
| Q37721802 | Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer |
| Q41635802 | Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification |
| Q24273274 | Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate |
| Q44039602 | Estrogen receptor gene amplification occurs rarely in ovarian cancer |
| Q36238509 | Estrogen receptor genes variations and breast cancer risk in Iran |
| Q33626091 | Estrogen receptor-beta gene polymorphism in women with breast cancer at the Imam Khomeini Hospital Complex, Iran |
| Q35000812 | Evaluation of functional genetic variants at 6q25.1 and risk of breast cancer in a Chinese population |
| Q38301592 | Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities |
| Q57793316 | Frequent ESR1 and CDK Pathway Copy Number Alterations in Metastatic Breast Cancer |
| Q39428484 | Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study |
| Q37261206 | Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line |
| Q94561690 | Genome-Wide Analysis of Methylation-Driven Genes and Identification of an Eight-Gene Panel for Prognosis Prediction in Breast Cancer |
| Q37005057 | Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis |
| Q33340988 | Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer |
| Q24610167 | Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer |
| Q55515610 | Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence. |
| Q61814553 | Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis |
| Q55024426 | Identification of Steroidogenic Components Derived From Gardenia jasminoides Ellis Potentially Useful for Treating Postmenopausal Syndrome. |
| Q41557019 | Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm |
| Q37453798 | Identifying estrogen receptor target genes. |
| Q36274172 | In vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells |
| Q36925229 | Inherited and acquired alterations in development of breast cancer. |
| Q46014808 | Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression. |
| Q37213805 | Integrated analysis of breast cancer cell lines reveals unique signaling pathways |
| Q26782613 | Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential |
| Q90576336 | Integrative omics analyses broaden treatment targets in human cancer |
| Q33520827 | Keratin 18 attenuates estrogen receptor alpha-mediated signaling by sequestering LRP16 in cytoplasm |
| Q52641460 | Key genes and regulatory networks involved in the initiation, progression and invasion of colorectal cancer. |
| Q92874799 | Knowledge-guided analysis of "omics" data using the KnowEnG cloud platform |
| Q97681241 | MAGPEL: an autoMated pipeline for inferring vAriant-driven Gene PanEls from the full-length biomedical literature |
| Q38439266 | Mechanisms of aromatase inhibitor resistance. |
| Q37832430 | Mechanisms of estrogen receptor-α upregulation in breast cancers |
| Q35682549 | MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers? |
| Q34512262 | Models of human core transcriptional regulatory circuitries |
| Q35696213 | Modulation of MicroRNAs by Chemical Carcinogens and Anticancer Drugs in Human Cancer: Potential Inkling to Therapeutic Advantage |
| Q33789215 | Modulation of human estrogen receptor α activity by multivalent estradiol-peptidomimetic conjugates |
| Q24610335 | Molecular biology of lung cancer: clinical implications |
| Q54482516 | Molecular copy-number counting: potential of single-molecule diagnostics. |
| Q55223470 | Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. |
| Q43062153 | Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes |
| Q39979970 | Musings on genome medicine: cancer genetics and the promise of effective treatment |
| Q33836777 | New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response |
| Q33693293 | Non-feminizing estrogens: a novel neuroprotective therapy |
| Q50668328 | Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. |
| Q60529808 | On the evidence for ESR1 amplification in breast cancer |
| Q36147178 | Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification |
| Q36087902 | PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells. |
| Q45352511 | PES1 differentially regulates the expression of ERα and ERβ in ovarian cancer |
| Q34943438 | Palindromic gene amplification--an evolutionarily conserved role for DNA inverted repeats in the genome |
| Q37062641 | Polygenic susceptibility to breast cancer: current state-of-the-art |
| Q36158021 | Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes |
| Q40248157 | Potentially functional variants in lncRNAs are associated with breast cancer risk in a Chinese population. |
| Q50734440 | Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures. |
| Q89537639 | Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer |
| Q38778532 | Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer |
| Q35909220 | Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial |
| Q54374707 | Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. |
| Q34951367 | Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients |
| Q34907190 | Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG) |
| Q53190494 | RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. |
| Q30494804 | Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study |
| Q24646768 | Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer |
| Q34194495 | Regulation of microRNAs by natural agents: new strategies in cancer therapies |
| Q37334047 | Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter |
| Q58079140 | Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals |
| Q35225077 | Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells |
| Q36640358 | S100A8/A9 is associated with estrogen receptor loss in breast cancer |
| Q40002893 | SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis |
| Q34084267 | SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells |
| Q35501899 | SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer |
| Q34310409 | Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women |
| Q39932632 | Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis |
| Q37687527 | Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers. |
| Q92145419 | Sparse quadratic classification rules via linear dimension reduction |
| Q43122076 | Targeted Chemotherapy with Metal Complexes |
| Q26783925 | Targeting Breast Cancer Metastasis |
| Q92126767 | The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer |
| Q57112955 | The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer |
| Q31140694 | The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. |
| Q33712095 | The role of MDM2 and MDM4 in breast cancer development and prevention. |
| Q28390036 | The role of cadmium and nickel in estrogen receptor signaling and breast cancer: metalloestrogens or not? |
| Q96342312 | The variable association between expression and methylation of estrogen receptors and the survival of patients with different tumors |
| Q39664547 | Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth |
| Q33570282 | Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis |
| Q80606168 | [Molecular high throughput research in prostate carcinoma] |
| Q64067053 | alterations and metastasis in estrogen receptor positive breast cancer |
| Q36216301 | p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells. |
Search more.